JP2023527775A - Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法 - Google Patents

Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法 Download PDF

Info

Publication number
JP2023527775A
JP2023527775A JP2022571133A JP2022571133A JP2023527775A JP 2023527775 A JP2023527775 A JP 2023527775A JP 2022571133 A JP2022571133 A JP 2022571133A JP 2022571133 A JP2022571133 A JP 2022571133A JP 2023527775 A JP2023527775 A JP 2023527775A
Authority
JP
Japan
Prior art keywords
inhibitor
subject
seq
treatment
eoe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571133A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021237110A5 (cg-RX-API-DMAC7.html
Inventor
ジェニファー・ディー・ハミルトン
ジェニファー・マロニー
レーダ・マンネン
マルセラ・ルディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2023527775A publication Critical patent/JP2023527775A/ja
Publication of JPWO2021237110A5 publication Critical patent/JPWO2021237110A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2022571133A 2020-05-22 2021-05-21 Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法 Pending JP2023527775A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202063029085P 2020-05-22 2020-05-22
US63/029,085 2020-05-22
US202063066705P 2020-08-17 2020-08-17
US63/066,705 2020-08-17
US202063071264P 2020-08-27 2020-08-27
US63/071,264 2020-08-27
US202063088147P 2020-10-06 2020-10-06
US63/088,147 2020-10-06
US202063121088P 2020-12-03 2020-12-03
US63/121,088 2020-12-03
US202163144939P 2021-02-02 2021-02-02
US63/144,939 2021-02-02
EP21315068 2021-04-21
EP21315068.3 2021-04-21
PCT/US2021/033693 WO2021237110A1 (en) 2020-05-22 2021-05-21 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Publications (2)

Publication Number Publication Date
JP2023527775A true JP2023527775A (ja) 2023-06-30
JPWO2021237110A5 JPWO2021237110A5 (cg-RX-API-DMAC7.html) 2024-05-28

Family

ID=76444669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571133A Pending JP2023527775A (ja) 2020-05-22 2021-05-21 Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法

Country Status (11)

Country Link
US (1) US20250154267A2 (cg-RX-API-DMAC7.html)
EP (1) EP4153300A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023527775A (cg-RX-API-DMAC7.html)
KR (1) KR20230015965A (cg-RX-API-DMAC7.html)
CN (1) CN115768516A (cg-RX-API-DMAC7.html)
AU (1) AU2021277398A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022235A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174431A1 (cg-RX-API-DMAC7.html)
IL (1) IL298257A (cg-RX-API-DMAC7.html)
MX (1) MX2022014440A (cg-RX-API-DMAC7.html)
WO (1) WO2021237110A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RU2698907C2 (ru) 2012-09-07 2019-09-02 Ридженерон Фармасьютикалз, Инк. Способы лечения атопического дерматита с помощью антагониста il-4r
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
MX376691B (es) 2014-02-28 2025-03-07 Regeneron Pharma Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
EA037960B1 (ru) 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
PT3506931T (pt) 2016-09-01 2024-08-21 Regeneron Pharma Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r
SG11202009371WA (en) 2018-05-13 2020-10-29 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r inhibitor
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
AU2023304436A1 (en) 2022-07-08 2025-02-20 Regeneron Pharmaceuticals, Inc. Methods for treating pediatric eosinophilic esophagitis by administering an il-4r antagonist
TW202502820A (zh) 2023-03-27 2025-01-16 美商再生元醫藥公司 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法
WO2025221247A1 (en) * 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528207A (ja) * 2013-07-11 2016-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒ阻害剤の投与による好酸球性食道炎を治療する方法
JP2020529434A (ja) * 2017-08-04 2020-10-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 活動性好酸球性食道炎を治療する方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292665B1 (en) 2000-05-26 2015-07-08 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI356064B (en) 2003-11-07 2012-01-11 Immunex Corp Antibodies that bind interleukin-4 receptor
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
US9334331B2 (en) * 2010-11-17 2016-05-10 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EA037960B1 (ru) * 2016-04-27 2021-06-15 Эббви Инк. Способ лечения эозинофильного эзофагита с применением антитела против il-13
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
TWI777515B (zh) * 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
RU2020128551A (ru) * 2018-02-21 2022-03-21 АДЭР ФАРМАСЬЮТИКАЛЗ ЮЭс, Л.П. Способы ведения эозинофильного эзофагита
CN120665147A (zh) * 2018-06-14 2025-09-19 味之素株式会社 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
WO2020096381A1 (ko) 2018-11-09 2020-05-14 아주대학교 산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528207A (ja) * 2013-07-11 2016-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒ阻害剤の投与による好酸球性食道炎を治療する方法
JP2020529434A (ja) * 2017-08-04 2020-10-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 活動性好酸球性食道炎を治療する方法

Also Published As

Publication number Publication date
AU2021277398A1 (en) 2023-02-02
WO2021237110A1 (en) 2021-11-25
KR20230015965A (ko) 2023-01-31
MX2022014440A (es) 2023-02-27
US20210363264A1 (en) 2021-11-25
EP4153300A1 (en) 2023-03-29
BR112022022235A2 (pt) 2023-03-28
CA3174431A1 (en) 2021-11-25
CN115768516A (zh) 2023-03-07
US20250154267A2 (en) 2025-05-15
IL298257A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
JP2023527775A (ja) Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
JP6637113B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
US11053309B2 (en) Methods for treating active eosinophilic esophagitis
KR102462039B1 (ko) Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
JP6861630B2 (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
KR20210132232A (ko) Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
AU2025200955A1 (en) Methods for treating active eosinophilic esophagitis
JP2019069987A (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻茸を処置する方法
US20240350626A1 (en) Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
JP2025522904A (ja) Ｉｌ－４ｒアンタゴニストを投与することによる小児好酸球性食道炎の処置方法
RU2848340C1 (ru) Способы лечения эозинофильного эзофагита путем введения ингибитора il-4r
JP2020059749A (ja) Ｉｌ−４ｒアンタゴニストを投与することによるアトピー性皮膚炎を処置するための方法
RU2776651C2 (ru) Способы лечения активного эозинофильного эзофагита
RU2777328C2 (ru) Способы предупреждения или лечения аллергии посредством введения антагониста il-4r
EA045955B1 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
HK1218854A1 (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
HK1218854B (en) Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251222